Last reviewed · How we verify
Consolidation Sintilimab
Sintilimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.
Sintilimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells. Used for Consolidation therapy in non-small cell lung cancer (NSCLC) following concurrent chemoradiotherapy.
At a glance
| Generic name | Consolidation Sintilimab |
|---|---|
| Sponsor | Shandong Cancer Hospital and Institute |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Sintilimab binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with PD-L1 and PD-L2 ligands expressed by tumor cells. This blockade restores anti-tumor immune responses by reactivating exhausted T cells. In consolidation therapy, it is used after initial treatment to maintain disease control and improve long-term outcomes.
Approved indications
- Consolidation therapy in non-small cell lung cancer (NSCLC) following concurrent chemoradiotherapy
Common side effects
- Fatigue
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Rash
Key clinical trials
- Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma (PHASE2)
- Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study (PHASE3)
- Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
- Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC (PHASE2)
- The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer (PHASE2)
- Serplulimab Combined With CCRT for LS-SCLC. (PHASE2)
- Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma (PHASE2)
- Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Consolidation Sintilimab CI brief — competitive landscape report
- Consolidation Sintilimab updates RSS · CI watch RSS
- Shandong Cancer Hospital and Institute portfolio CI